v3.26.1
Document and Entity Information
 12 Months Ended
Dec. 31, 2025
shares
Document Information [Line Items]  
Document Type 20-F
Amendment Flag false
Document Period End Date Dec. 31, 2025
Document Fiscal Year Focus 2025
Document Fiscal Period Focus FY
Entity Registrant Name SINOVAC BIOTECH LTD
Entity Central Index Key 0001084201
Current Fiscal Year End Date --12-31
Entity Well-known Seasoned Issuer No
Entity Voluntary Filers No
Entity Current Reporting Status No
Entity Interactive Data Current Yes
Entity Filer Category Accelerated Filer
Entity Emerging Growth Company false
ICFR Auditor Attestation Flag true
Document Financial Statement Error Correction [Flag] false
Entity Shell Company false
Entity File Number 001-32371
Entity Incorporation, State or Country Code B9
Entity Address, Address Line One No. 39 Shangdi Xi Road
Entity Address, Address Line Two Haidian District
Entity Address, City or Town Beijing
Entity Address, Country CN
Entity Address, Postal Zip Code 100085
Entity Common Stock, Shares Outstanding 71,860,702
Document Annual Report true
Document Transition Report false
Document Shell Company Report false
Document Registration Statement false
Entity Bankruptcy Proceedings, Reporting Current false
Document Accounting Standard U.S. GAAP
Auditor Firm ID 1921
Auditor Name Zhonghua Certified Public Accountants LLP
Auditor Location Shanghai, China
Auditor Opinion [Text Block]

We have audited the accompanying consolidated balance sheets of Sinovac Biotech Ltd. and its subsidiaries (the Company) as of December 31, 2025 and 2024, and the related consolidated statements of operations and comprehensive income (loss), shareholders' equity, and cash flows for each of the years in the three-year period ended December 31, 2025, and the related notes (collectively referred to as the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the years in the three-year period ended December 31, 2025, in conformity with accounting principles generally accepted in the United States of America.

 

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2025, based on criteria established in Internal Control—Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO), and our report dated June 5, 2026 expressed an adverse opinion.

Common Stock  
Document Information [Line Items]  
Title of 12(b) Security Common Shares, par value $0.001 per share
Security Exchange Name NASDAQ
Trading Symbol SVA
Business Contact  
Document Information [Line Items]  
Entity Address, Address Line One No. 39 Shangdi Xi Road
Entity Address, Address Line Two Haidian District
Entity Address, City or Town Beijing
Entity Address, Country CN
Entity Address, Postal Zip Code 100085
Contact Personnel Name Nan Wang
City Area Code +86
Local Phone Number 10-5693-1800
Contact Personnel Fax Number +86-10-5693-1800
Contact Personnel Email Address ir@sinovac.com